Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Changzhou Xiangming Intelligent Drive System Corporation
SZSE:301226
|
CN |
Galmed Pharmaceuticals Ltd
Free Cash Flow
Galmed Pharmaceuticals Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
|
Free Cash Flow
-$6.3m
|
CAGR 3-Years
30%
|
CAGR 5-Years
25%
|
CAGR 10-Years
3%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Free Cash Flow
$15.6m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Free Cash Flow
-$10.5m
|
CAGR 3-Years
31%
|
CAGR 5-Years
3%
|
CAGR 10-Years
2%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Free Cash Flow
-$162.7m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Free Cash Flow
-$7.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Free Cash Flow
-$22m
|
CAGR 3-Years
12%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-1%
|
|
Galmed Pharmaceuticals Ltd
Glance View
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
See Also
What is Galmed Pharmaceuticals Ltd's Free Cash Flow?
Free Cash Flow
-6.3m
USD
Based on the financial report for Dec 31, 2025, Galmed Pharmaceuticals Ltd's Free Cash Flow amounts to -6.3m USD.
What is Galmed Pharmaceuticals Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
3%
Over the last year, the Free Cash Flow growth was -7%. The average annual Free Cash Flow growth rates for Galmed Pharmaceuticals Ltd have been 30% over the past three years , 25% over the past five years , and 3% over the past ten years .
